Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846 · see citing works

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709 · see citing works

Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>

Ettinger, B. (1999) · JAMA · doi:10.1001/jama.282.7.637 · Cited by 3,366 · see citing works

Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · see citing works

Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral Fractures<SUBTITLE>Results From the Fracture Intervention Trial</SUBTITLE>

Cummings, S. R. (1998) · JAMA · doi:10.1001/jama.280.24.2077 · Cited by 2,277 · see citing works

Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis

Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J. A., Downs, R. W., Dequeker, J., Favus, M. J., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,276 · see citing works

Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis

Reginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580 · see citing works

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study

Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122 · see citing works

Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study

Garnero, P., Hausherr, E., Chapuy, M. C., Marcelli, C., Grandjean, H., Müller, C., Cormier, C., Bréart, G., Meunier, P. J., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 984 · see citing works

Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis

Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P. D., Woodson, G. C., Yanover, M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 947 · see citing works

Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal Osteoporosis

Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sørensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 932 · see citing works

Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis

Petitti, D. B. (1999) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195133646.001.0001 · Cited by 928 · see citing works

Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen

Lufkin, E. G., Wahner, H. W., O’Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., & Riggs, B. L. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-1-1 · Cited by 813 · see citing works

Estrogen Replacement Therapy and Fractures in Older Women

Cauley, J. A., Seeley, D. G., Ensrud, K. E., Ettinger, B., Black, D., & Cummings, S. R. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-1-199501010-00002 · Cited by 808 · see citing works

Bone Compressive Strength: The Influence of Density and Strain Rate

Carter, D. R., & Hayes, W. C. (1976) · Science · doi:10.1126/science.996549 · Cited by 709 · see citing works

Statistical validation of intermediate endpoints for chronic diseases

Freedman, L. S., Graubard, B. I., & Schatzkin, A. G. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651 · see citing works

Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

Overgaard, K., Hansen, M. A., Jensen, S. B., & Christiansen, C. (1992) · BMJ · doi:10.1136/bmj.305.6853.556 · Cited by 426 · see citing works

Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density

Wasnich, R. D., & Miller, P. D. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6267 · Cited by 402 · see citing works

The Biological Standardization of Insulin

Fieller, E. C. (1941) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.2307/2983630 · Cited by 356 · see citing works

Trabecular bone architecture in the pathogenesis and prevention of fracture

PARFITT, A. M. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90274-9 · Cited by 350 · see citing works

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy

Harris, S. T., Watts, N. B., Jackson, R. D., Genant, H. K., Wasnich, R. D., Ross, P. D., Miller, P. D., Licata, A. A., & Chesnut, C. H. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90350-x · Cited by 349 · see citing works

A 20-Year Perspective on the Mechanical Properties of Trabecular Bone

Keaveny, T. M., & Hayes, W. C. (1993) · Journal of Biomechanical Engineering · doi:10.1115/1.2895536 · Cited by 318 · see citing works

Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk?

Faulkner, K. G. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.2.183 · Cited by 205 · see citing works

Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy

Riggs, B. L., Melton, L. J., & O’Fallon, W. M. (1996) · Bone · doi:10.1016/8756-3282(95)00502-1 · Cited by 187 · see citing works

Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches

Black, D. M., Palermo, L., Nevitt, M. C., Genant, H. K., Christensen, L., & Cummings, S. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.90 · Cited by 186 · see citing works

Vertebral structure and strengthIn vivo andIn vitro

Mosekilde, L. (1993) · Calcified Tissue International · doi:10.1007/bf01673420 · Cited by 159 · see citing works

Architecture and vertebral fracture

Recker, R. R. (1993) · Calcified Tissue International · doi:10.1007/bf01673423 · Cited by 144 · see citing works

Effect of menopause on femoral and vertebral bone loss

Pouillès, J. M., Trémollières, F., & Ribot, C. A. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101014 · Cited by 91 · see citing works

Parathyroid hormone 1–34 (hpth 1–34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis — results from a placebo‐controlled randomized trial

Arnaud, C. D., Roe, E. B., Sanchez, S., del Puerto, G. A., Pierni, E., Bachetti, P., & Cann, C. F. (2000) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(00)82061-5 · Cited by 68 · see citing works

Prediction of Vertebral and Femoral Strength In Vitro by Bone Mineral Density Measured at Different Skeletal Sites

Cheng, X. G., Lowet, G., Boonen, S., Nicholson, P., der Perre, G. V., & Dequeker, J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.9.1439 · Cited by 60 · see citing works

Comparison of rates of bone loss from the spine measured using two manufacturers' densitometers

Peel, N. F. A., & Eastell, R. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101124 · Cited by 42 · see citing works

Changing perceptions in osteoporosis Commentary: Bone density can be used to assess fracture risk

Wilkin, T. J., & Eastell, R. (1999) · BMJ · doi:10.1136/bmj.318.7187.862 · Cited by 42 · see citing works

Statistical Validation of Surrogate Endpoints: Problems and Proposals

Buyse, M. E., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Drug Information Journal · doi:10.1177/009286150003400213 · Cited by 27 · see citing works

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis

Loeliger, E. A. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80150-8 · Cited by 14 · see citing works

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,954 · see citing works

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900 · see citing works

Epidemiology, etiology, and diagnosis of osteoporosis

Lane, N. E. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.08.047 · Cited by 1,300 · see citing works

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212 · see citing works

From Estrogen-Centric to Aging and Oxidative Stress: A Revised Perspective of the Pathogenesis of Osteoporosis

Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,210 · see citing works

The Epidemiology of Distal Radius Fractures

Nellans, K. W., Kowalski, E., & Chung, K. C. (2012) · Hand Clinics · doi:10.1016/j.hcl.2012.02.001 · Cited by 902 · see citing works

Estrogens and androgens in skeletal physiology and pathophysiology

Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860 · see citing works

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

Kanis, J. А., Burlet, N., Cooper, C. C., Delmas, P. D., Reginster, J., Borgström, F., & Rizzoli, R. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 778 · see citing works

Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment

Marx, R. E., Cillo, J. E., & Ulloa, J. J. (2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2007.08.003 · Cited by 756 · see citing works

Osteoporosis

Ensrud, K. E., & Crandall, C. J. (2017) · Annals of Internal Medicine · doi:10.7326/aitc201708010 · Cited by 730 · see citing works

Skeletal Involution by Age-associated Oxidative Stress and Its Acceleration by Loss of Sex Steroids

Almeida, M., Li, H., Martín-Millán, M., Plotkin, L. I., Stewart, S. A., Roberson, P. K., Kousteni, S., O’Brien, C. A., Bellido, T., PARFITT, A. M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702810200 · Cited by 707 · see citing works

Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of physicians

Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676 · see citing works

One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis

Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T. F., Lang, T., McGowan, J., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 612 · see citing works

Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate

Eastell, R., Barton, I. P., Hannon, R., Chines, A. A., Garnero, P., & Delmas, P. D. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 585 · see citing works

Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

Khosla, S., Burr, D., Cauley, J., Dempster, D., Ebeling, P., Felsenberg, D., Gagel, R., Gilsanz, V., Guise, T., Koka, S., et al. (2008) · Journal of oral and maxillofacial surgery · doi:10.1016/j.joms.2008.01.054 · Cited by 392 · see citing works

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial

Silverman, S. L., Christiansen, C., Genant, H. K., Vukičević, S., Zanchetta, J., de Villiers, T. J., Constantine, G. D., & Chines, A. A. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080710 · Cited by 507 · see citing works

Clinical Use of Quantitative Computed Tomography and Peripheral Quantitative Computed Tomography in the Management of Osteoporosis in Adults: The 2007 ISCD Official Positions

Engelke, K., Adams, J. E., Armbrecht, G., Augat, P., Bogado, C. E., Bouxsein, M. L., Felsenberg, D., Ito, M., Prevrhal, S., Hans, D. B., et al. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2007.12.010 · Cited by 617 · see citing works

Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis

Langdahl, B. L., Ferrari, S., & Dempster, D. W. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16670154 · Cited by 439 · see citing works

Periosteum: biology, regulation, and response to osteoporosis therapies

Allen, M. R., Hock, J. M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.07.014 · Cited by 433 · see citing works

Bone Quality: The Determinants of Bone Strength and Fragility

Fonseca, H., Moreira‐Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2013) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 435 · see citing works

Pathophysiology of Osteoporosis

Armas, L. A. G., & Recker, R. R. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.006 · Cited by 466 · see citing works

NCCN Task Force Report: Bone Health in Cancer Care

Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R. R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 411 · see citing works

What old means to bone

Manolagas, S. C., & Parfitt, A. M. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.01.010 · Cited by 404 · see citing works

Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial

Bauer, D. C., Black, D. M., Garnero, P., Hochberg, M. C., Ott, S. M., Orloff, J. J., Thompson, D. E., Ewing, S. K., Delmas, P. D., & for the Fracture Intervention Trial Study Group (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040512 · Cited by 403 · see citing works

The role of cortical bone and its microstructure in bone strength

Augat, P., & Schorlemmer, S. (2006) · Age and Ageing · doi:10.1093/ageing/afl081 · Cited by 378 · see citing works

The Assessment of Fracture Risk

Unnanuntana, A., Gladnick, B. P., Donnelly, E. L., & Lane, J. M. (2010) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.i.00919 · Cited by 372 · see citing works

A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis

Body, J., Gaich, G. A., Scheele, W. H., Kulkarni, P. M., Miller, P. D., Peretz, A., Dore, R. K., Correa‐Rotter, R., Παπαϊωάννου, Α., Cumming, D. C., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020334 · Cited by 365 · see citing works

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

Bouxsein, M., Eastell, R., Lui, L., Wu, L., de Papp, A. E., Grauer, A., Marín, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 355 · see citing works

Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study

Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M. R., Miller, P. D., Broy, S. B., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345 · see citing works

Bone Remodeling Increases Substantially in the Years After Menopause and Remains Increased in Older Osteoporosis Patients

Recker, R. R., Lappe, J. M., Davies, K. M., & Heaney, R. P. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040710 · Cited by 342 · see citing works

The bone quality framework: Determinants of bone strength and their interrelationships, and implications for osteoporosis management

Felsenberg, D., & Boonen, S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2004.12.020 · Cited by 342 · see citing works

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

Joint IOF-ECTS GIO Guidelines Working Group, Lekamwasam, S., Adachi, J. D., Agnusdei, D., Bilezikian, J. P., Boonen, S., Borgström, F., Cooper, C. C., Díez‐Pérez, A., Eastell, R., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-1958-1 · Cited by 335 · see citing works

The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial

Clowes, J. A., Peel, N. F. A., & Eastell, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030501 · Cited by 334 · see citing works

Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis

Lindsay, R., Scheele, W. H., Neer, R. M., Pohl, G. M., Adami, S., Mautalén, C., Reginster, J., Stepan, J. J., Myers, S. L., & Mitlak, B. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.18.2024 · Cited by 331 · see citing works

A biomechanical perspective on bone quality

Hernandez, C. J., & Keaveny, T. M. (2006) · Bone · doi:10.1016/j.bone.2006.06.001 · Cited by 321 · see citing works

Prevention and management of osteoporosis

McClung, M. R. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(02)00080-5 · Cited by 320 · see citing works

Hip Fractures and the Contribution of Cortical Versus Trabecular Bone to Femoral Neck Strength

Holzer, G., von Skrbensky, G., Holzer, L. A., & Pichl, W. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081108 · Cited by 319 · see citing works

Cortical and Trabecular Load Sharing in the Human Vertebral Body

Eswaran, S. K., Gupta, A. K., Adams, M. F., & Keaveny, T. M. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2006.21.2.307 · Cited by 308 · see citing works

Is the paradigm shifting?

Heaney, R. P. (2003) · Bone · doi:10.1016/s8756-3282(03)00236-9 · Cited by 306 · see citing works

Differential Genetic Effects of <EMPH TYPE="ITAL">ESR1</EMPH> Gene Polymorphisms on Osteoporosis Outcomes

Ioannidis, J. P. A. (2004) · JAMA · doi:10.1001/jama.292.17.2105 · Cited by 297 · see citing works

Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy

Delmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294 · see citing works

Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension

Ensrud, K. E., Barrett-Connor, E. L., Schwartz, A. V., Santora, A. C., Bauer, D. C., Suryawanshi, S., Feldstein, A. C., Haskell, W. L., Hochberg, M. C., Torner, J. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040326 · Cited by 273 · see citing works

Microindentation for in vivo measurement of bone tissue mechanical properties in humans

Díez‐Pérez, A., Güerri‐Fernández, R., Nogués, X., Cáceres, E., Peña, M. J., Mellibovsky, L., Randall, C. J., Bridges, D. C., Weaver, J. C., Proctor, A., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.73 · Cited by 269 · see citing works

Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability

Bellido, T., & Plotkin, L. I. (2010) · Bone · doi:10.1016/j.bone.2010.08.008 · Cited by 265 · see citing works

Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis

Keaveny, T. M., Donley, D. W., Hoffmann, P. F., Mitlak, B., Glass, E. V., & Martin, J. A. S. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061011 · Cited by 259 · see citing works

Postmenopausal Osteoporosis

Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043801 · Cited by 254 · see citing works

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate

Allen, M. R., Iwata, K., Phipps, R. J., & Burr, D. B. (2006) · Bone · doi:10.1016/j.bone.2006.04.028 · Cited by 253 · see citing works

Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures

Crandall, C. J., Newberry, S. J., Diamant, A. L., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 257 · see citing works

Bisphosphonates for steroid-induced osteoporosis

Allen, C., Yeung, J. H., Vandermeer, B., & Homik, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001347.pub2 · Cited by 250 · see citing works

Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study

Siris, E. S., Harris, S. T., Eastell, R., Zanchetta, J., Goemaere, S., Díez‐Pérez, A., Stock, J. L., Song, J., Qu, Y., Kulkarni, P. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050509 · Cited by 243 · see citing works

Regional variation in vertebral bone morphology and its contribution to vertebral fracture strength

Hulme, P. A., Boyd, S. K., & Ferguson, S. J. (2007) · Bone · doi:10.1016/j.bone.2007.08.019 · Cited by 240 · see citing works

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

Black, D. M., Bauer, D. C., Vittinghoff, E., Lui, L., Grauer, A., Marín, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 241 · see citing works

Fracture risk remains reduced one year after discontinuation of risedronate

Watts, N. B., Chines, A. A., Olszynski, W. P., McKeever, C., McClung, M. R., Zhou, X., & Grauer, A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0460-7 · Cited by 234 · see citing works

Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study

Miller, P. D., Chines, A. A., Christiansen, C., Hoeck, H. C., Kendler, D. L., Lewiecki, E. M., Woodson, G. C., Levine, A. B., Constantine, G. D., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071206 · Cited by 236 · see citing works

Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate

Watts, N. B., Cooper, C. C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T. P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 228 · see citing works

Treatment failure in osteoporosis

for the IOF CSA Inadequate Responders Working Group, Díez‐Pérez, A., Adachi, J. D., Agnusdei, D., Bilezikian, J. P., Compston, J. E., Cummings, S. R., Eastell, R., Eriksen, E. F., González-Macı́as, J., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2093-8 · Cited by 227 · see citing works

Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates

Licata, A. A. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e357 · Cited by 221 · see citing works

Bone turnover markers: understanding their value in clinical trials and clinical practice

Civitelli, R., Armamento‐Villareal, R., & Napoli, N. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0838-9 · Cited by 214 · see citing works

Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts In Vivo

Plotkin, L. I., Lezcano, V., Thostenson, J., Weinstein, R. S., Manolagas, S. C., & Bellido, T. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080617 · Cited by 214 · see citing works

Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures

Donnelly, E. L., Meredith, D. S., Nguyen, J., Gladnick, B. P., Rebolledo, B. J., Shaffer, A. D., Lorich, D. G., Lane, J. M., & Boskey, A. L. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.560 · Cited by 211 · see citing works

Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk

Sarkar, S., Reginster, J., Crans, G. G., Díez‐Pérez, A., Pinette, K. V., & Delmas, P. D. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301243 · Cited by 210 · see citing works

Antiresorptive therapies for osteoporosis: a clinical overview

Chen, J. S., & Sambrook, P. N. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.146 · Cited by 209 · see citing works

Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex

Donnelly, E. L., Boskey, A. L., Baker, S. P., & van der Meulen, M. C. H. (2009) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32442 · Cited by 194 · see citing works

Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence

Boonen, S., Bischoff-Ferrari, H. A., Cooper, C. C., Lips, P. T. A. M., Ljunggren, Ö., Meunier, P. J., & Reginster, J.-Y. (2006) · Calcified Tissue International · doi:10.1007/s00223-005-0009-8 · Cited by 189 · see citing works

Osteoporosis

Ensrud, K. E., & Crandall, C. J. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202401160 · Cited by 187 · see citing works

Transmenopausal changes in the trabecular bone structure

Akhter, M. P., Lappe, J. M., Davies, K. M., & Recker, R. R. (2007) · Bone · doi:10.1016/j.bone.2007.03.019 · Cited by 181 · see citing works

Monitoring Osteoporosis Therapy: Bone Mineral Density, Bone Turnover Markers, or Both?

Bonnick, S. L., & SHULMAN, L. P. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.12.020 · Cited by 182 · see citing works

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

Austin, M., Yang, Y., Vittinghoff, E., Adami, S., Boonen, S., Bauer, D. C., Bianchi, G., Bolognese, M. A., Christiansen, C., Eastell, R., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1472 · Cited by 182 · see citing works

Bisphosphonates for the prevention and treatment of osteoporosis

Maraka, S., & Kennel, K. A. (2015) · BMJ · doi:10.1136/bmj.h3783 · Cited by 178 · see citing works

The pathogenesis, diagnosis, investigation and management of osteoporosis

Sandhu, S. K., & Hampson, G. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.077842 · Cited by 173 · see citing works

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

Recker, R. R., Stakkestad, J. A., Chesnut, C. H., Christiansen, C., Skag, A., Høiseth, A. D., Ettinger, M. P., Mahoney, P., Schimmer, R. C., & Delmas, P. D. (2004) · Bone · doi:10.1016/j.bone.2004.01.008 · Cited by 172 · see citing works

Percutaneous Vertebroplasty for Osteoporotic Compression Fracture: Multivariate Study of Predictors of New Vertebral Body Fracture

Komemushi, A., Tanigawa, N., Kariya, S., Kojima, H., Shomura, Y., Komemushi, S., & Sawada, S. (2006) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-005-0138-5 · Cited by 170 · see citing works

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

Emkey, R. D., Koltun, W. D., Beusterien, K. M., Seidman, L. S., Kivitz, A., Devas, V., & Masanauskaite, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x74862 · Cited by 167 · see citing works

Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study

Simon, J. A., Lewiecki, E. M., Smith, M. E., Petruschke, R. A., Wang, L., & Palmisano, J. J. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80085-6 · Cited by 170 · see citing works

Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis

Yamazaki, S., Ichimura, S., Iwamoto, J., Takeda, T., & Toyama, Y. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0514-2 · Cited by 169 · see citing works

Effects of Salmon Calcitonin on Trabecular Microarchitecture as Determined by Magnetic Resonance Imaging: Results From the QUEST Study

Chesnut, C. H., Majumdar, S., Newitt, D. C., Shields, A., Van Pelt, J., Laschansky, E., Azria, M., Kriegman, A., Olson, M., Eriksen, E. F., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050411 · Cited by 163 · see citing works

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis

Cummings, S. R., Cosman, F., Lewiecki, E. M., Schousboe, J. T., Bauer, D. C., Black, D. M., Brown, T. D., Cheung, A. M., Cody, K., Cooper, C. C., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3039 · Cited by 165 · see citing works

Relationship Between Changes in BMD and Nonvertebral Fracture Incidence Associated With Risedronate: Reduction in Risk of Nonvertebral Fracture Is Not Related to Change in BMD

Watts, N. B., Geusens, P., Barton, I. P., & Felsenberg, D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050814 · Cited by 164 · see citing works

Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs

Plotkin, L. I., Manolagas, S. C., & Bellido, T. (2006) · Bone · doi:10.1016/j.bone.2006.02.060 · Cited by 163 · see citing works

Qualitative and quantitative ultrashort‐TE MRI of cortical bone

Du, J., & Bydder, G. M. (2012) · NMR in Biomedicine · doi:10.1002/nbm.2906 · Cited by 156 · see citing works

Monitoring Teriparatide-Associated Changes in Vertebral Microstructure by High-Resolution CT In Vivo: Results From the EUROFORS Study

Graeff, C., Timm, W., Nickélsen, T., Farrerons, J., Marín, F., Barker, C., & Glüer, C. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070603 · Cited by 159 · see citing works

Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide-Treated Postmenopausal Women With Osteoporosis

Chen, P., Miller, P. D., Delmas, P. D., Misurski, D. A., & Krege, J. H. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060802 · Cited by 157 · see citing works

Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long-Term Bisphosphonates: A Bone Biopsy Study

Chapurlat, R. D., ARLOT, M. E., Burt‐Pichat, B., Chavassieux, P., Roux, J. P., Portero-Muzy, N., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070609 · Cited by 154 · see citing works

Combination Therapy With Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women

Greenspan, S. L., Resnick, N. M., & Parker, R. A. (2003) · JAMA · doi:10.1001/jama.289.19.2525 · Cited by 153 · see citing works

A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: The oral calcitonin in postmenopausal osteoporosis (ORACAL) trial

Binkley, N., Bolognese, M., Sidorowicz-Bialynicka, A., Vally, T., Trout, R., Miller, C., Buben, C. E., Gilligan, J. P., Krause, D. S., & for the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1602 · Cited by 149 · see citing works

Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses

Ghogomu, E. A. T., Maxwell, L. J., Buchbinder, R., Rader, T., Pardo, J. P., Johnston, R. V., Christensen, R., Rutjes, A. W., Winzenberg, T. M., Singh, J. A., et al. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.121306 · Cited by 150 · see citing works

Influence of bone volume fraction and architecture on computed large-deformation failure mechanisms in human trabecular bone

Bevill, G. R., Eswaran, S. K., Gupta, A. K., Papadopoulos, P., & Keaveny, T. M. (2006) · Bone · doi:10.1016/j.bone.2006.06.016 · Cited by 148 · see citing works

Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years

Bonnick, S. L., Saag, K. G., Kiel, D. P., McClung, M. R., Hochberg, M. C., Burnett‐Bowie, S. M., Sebba, A. I., Kagan, R., Chen, E., Thompson, D. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2602 · Cited by 146 · see citing works

Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo‐controlled trial

Zein, C. O., Jorgensen, R. A., Clarke, B., Wenger, D. E., Keach, J. C., Angulo, P., & Lindor, K. D. (2005) · Hepatology · doi:10.1002/hep.20866 · Cited by 142 · see citing works

Calcium and vitamin D in the prevention and treatment of osteoporosis – a clinical update

Boonen, S., Vanderschueren, D., Haentjens, P., & Lips, P. T. A. M. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01655.x · Cited by 140 · see citing works

Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra

Allen, M. R., Gineyts, É., Leeming, D. J., Burr, D. B., & Delmas, P. D. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0533-7 · Cited by 139 · see citing works

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

Miller, P. D., Wagman, R. B., Peacock, M., Lewiecki, E. M., Bolognese, M. A., Weinstein, R. L., Ding, B., Martín, J. S., & McClung, M. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1805 · Cited by 140 · see citing works

Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P. G., Duffin, K. L., Barascuk, N., Klickstein, L. B., Aggarwal, P., Nemirovskiy, O. V., Byrjalsen, I., et al. (2009) · Biomarkers · doi:10.1080/13547500902777608 · Cited by 135 · see citing works

Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)

Nishizawà, Y., Ohta, H., Miura, M., Inaba, M., Ichimura, S., Shiraki, M., Takada, J., Chaki, O., Hagino, H., Fujiwara, S., et al. (2012) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-012-0392-y · Cited by 133 · see citing works

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

Chapurlat, R. D., Palermo, L., Ramsay, P., & Cummings, S. R. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1770-7 · Cited by 133 · see citing works

Does osteoporosis therapy invalidate FRAX for fracture prediction?

Leslie, W. D., Lix, L. M., Johansson, H., Odén, A., McCloskey, E. V., Kanis, J. А., & Program, F. T. M. B. D. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1582 · Cited by 132 · see citing works

Perspective: Reconsidering the Effects of Antiresorptive Therapies in Reducing Osteoporotic Fracture

Chesnut, C. H., & Rosen, C. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.12.2163 · Cited by 130 · see citing works

Is bone mineral density predictive of fracture risk reduction?

Cefalu, C. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125003062 · Cited by 132 · see citing works

Femoral Neck Bone Loss Predicts Fracture Risk Independent of Baseline BMD

Nguyen, T. V., & Eisman, J. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050215 · Cited by 131 · see citing works

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

Jacques, R., Boonen, S., Cosman, F., Reid, I. R., Bauer, D. C., Black, D. M., & Eastell, R. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1644 · Cited by 129 · see citing works

How drugs decrease fracture risk: lessons from trials.

Cummings (2002) · PubMed · Cited by 31 · see citing works

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

Chapurlat, R. D., Palermo, L., Ramsay, P., & Cummings, S. R. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1770-7 · Cited by 133 · see citing works

Arthritis of the finger joints: A comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging

Backhaus, M., Kamradt, T., SANDROCK, D., Loreck, D., Fritz, J., Wolf, K.-J., Raber, H., Hamm, B., Burmester, G. R., & BOLLOW, M. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6 · Cited by 642 · see citing works

Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate

Watts, N. B., Cooper, C. C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T. P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 228 · see citing works

OP0113 Increases in bone mineral density explain the reduction in incidence of nonvertebral fractures seen with antiresorptive therapy in women with postmenopausal osteoporosis

Wasnich, R. D., Mc, H., Greenspan, S. L., Ross, P., & Miller, P. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2001.634